Diagnostic accuracy of a novel point‐of‐care test for simultaneous detection of anti‐transglutaminase IgA and anti‐deamidated gliadin IgG antibodies
Journal of Clinical Laboratory Analysis · 2024-02 · 38 (3)
DOI: 10.1002/jcla.25003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 30.01.2024. Verfasst von Giuseppe Parrinello und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Allergy Unit, Santa Maria degli Angeli Hospital, Pordenone, Italy. Hauptthemen laut MEDLINE: Transglutaminases, Celiac Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: PRIMA Lab SA.
Abstract (Originalsprache)
Background
Point‐of‐care tests (POCTs) may have a role in detecting undiagnosed cases of Celiac disease (CD). We assessed the diagnostic accuracy of a novel POCT, compared with the conventional serological methods, for simultaneous anti‐transglutaminase (tTG) IgA and anti‐deamidated gliadin (DGP) IgG antibody detection. Furthermore, we evaluated the effect of different biological matrices (whole blood and serum) on test performance.
Methods
Serum and whole blood from celiac or suspected celiac patients who underwent duodenal biopsy were assayed for the presence of anti‐tTG IgA and anti‐DGP IgG both with the reference standard methods (Thermo Fisher Scientific, Uppsala, Sweden) and with the POCT (PRIMA Lab SA, Balerna, Switzerland).
Results
266 sera (101 negative and 165 positive) and 60 whole blood samples (34 positive and 26 negative) were included in the study. POCT for anti‐DGP IgG showed a sensitivity of 84.3% and a specificity of 90.1%, with positive (PPV) and negative predictive values (NPV) of 91.07% and 82.73%. POCT for anti‐tTG IgA showed a sensitivity of 98.31% and a specificity of 98.02%, with a PPV and NPV of 98.31% and 98.02%. Test accuracies were 86.94% and 98.17%, respectively. The agreement of the results between the two different matrices showed a strong correlation rate: 95% for anti‐DGP IgG and 100% for anti‐tTG IgA.
Conclusion
The anti‐tTG IgA/anti‐DGP IgG‐based POCT showed good diagnostic accuracy with comparable sensitivities and specificities to reference standard methods in detecting CD in symptomatic patients and could be considered as a mass screening test before referring to conventional serology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology and Allergy Unit, Santa Maria degli Angeli Hospital, Pordenone, Italy.
- PRIMA Lab SA Laboratories, Balerna, Switzerland.
ORCID-Profile: Giuseppe Parrinello, Mirella Da Re, Simone Camelliti, Marzia Cozzi, Danilo Villalta
Förderung
- PRIMA Lab SA
Zitieren
APA
Parrinello, G., Da Re, M., Grizzo, F., Camelliti, S., Cozzi, M., Marinoni, F., & Villalta, D. (2024). Diagnostic accuracy of a novel point‐of‐care test for simultaneous detection of anti‐transglutaminase IgA and anti‐deamidated gliadin IgG antibodies. Journal of Clinical Laboratory Analysis, 38(3). https://doi.org/10.1002/jcla.25003
Vancouver
Parrinello G, Da Re M, Grizzo F, Camelliti S, Cozzi M, Marinoni F, et al. Diagnostic accuracy of a novel point‐of‐care test for simultaneous detection of anti‐transglutaminase IgA and anti‐deamidated gliadin IgG antibodies. Journal of Clinical Laboratory Analysis. 2024;38(3). doi:10.1002/jcla.25003
BibTeX
@article{Parrinello2024,
author = {Parrinello, Giuseppe and Da Re, Mirella and Grizzo, Francesca and Camelliti, Simone and Cozzi, Marzia and Marinoni, Francesca and Villalta, Danilo},
title = {Diagnostic accuracy of a novel point‐of‐care test for simultaneous detection of anti‐transglutaminase IgA and anti‐deamidated gliadin IgG antibodies},
journal = {Journal of Clinical Laboratory Analysis},
year = {2024},
volume = {38},
number = {3},
doi = {10.1002/jcla.25003}
}
EUVIMED